Dual Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke: A Ghost from the Past or a New Frontier?
2010

Dual Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke

Sample size: 20332 publication 10 minutes Evidence: moderate

Author Information

Author(s): Clotilde Balucani, Kristian Barlinn, Zeljko Zivanovic, Lucilla Parnetti, Mauro Silvestrini, Andrei V. Alexandrov

Primary Institution: University of Alabama at Birmingham

Hypothesis

Is dual antiplatelet therapy more effective than aspirin alone in preventing recurrent ischemic strokes?

Conclusion

Dual antiplatelet therapy may provide better prevention of recurrent ischemic events compared to aspirin alone, especially in the early phase after a stroke or TIA.

Supporting Evidence

  • Aspirin reduces the risk of recurrent stroke by 20–30%.
  • The combination of aspirin and ER-dipyridamole significantly reduces the risk of recurrent stroke.
  • Clopidogrel shows a relative risk reduction in serious vascular events compared to aspirin.

Takeaway

This study looks at how two types of medicine can help prevent strokes. Using both together might work better than just one.

Methodology

The study reviews data from various clinical trials comparing the efficacy of dual antiplatelet therapy versus monotherapy in stroke prevention.

Potential Biases

Potential biases may arise from the selection of trials and the interpretation of their results.

Limitations

The study does not evaluate the acute period after a stroke or TIA, and the safety and efficacy during this time are unknown.

Participant Demographics

The study includes patients with a history of ischemic stroke or TIA, with a focus on high-risk individuals.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI 0.66–0.98

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.4061/2010/427418

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication